INTRODUCTION
The idea of constructing a glossary of terms related to pharmaceutics was raised first at the meeting of the Section on Medicinal Chemistry of the Chemistry and Human Health Division in 1999, and became a recognized project in 2001. Prior to this glossary, the Chemistry and Human Health Division did not deal with the areas of pharmacy and pharmaceutics, although the Section on Medicinal Chemistry has dealt with closely related subjects such as toxicology, drug metabolism, pharmaceutically acceptable drug salts, training and research in medicinal chemistry in developing countries and the Glossary of Terms used in Medicinal Chemistry, as well as some other topics.
Pharmaceutics is defined in this glossary as the science of preparation of drugs, dosage forms. and drug delivery systems, taking into account the pharmacokinetics and pharmacodynamics of the drug as well as its physical and chemical properties. Thus, many branches of chemistry such as organic, inorganic, solid-state, colloid, and surface chemistry, as well as nanotechnology and others, play roles in pharmaceutics. Even the more biologically oriented branch of pharmaceutics, i.e., biopharmaceutics, draws on chemical concepts such as (pharmaco)kinetics, absorption, dissolution, diffusion, and others. Therefore, it appears timely for IUPAC to publish recommendations in this area.
The glossary was first given the title "Glossary of Terms in Pharmaceutical Technology". Over the years, this title underwent a few changes until it has become the present one. During the review process, a communication from the U.S. Pharmacopoeia (USP) indicated concern regarding some definitions that differ from those of the Pharmacopoeia. The Subcommittee on Medicinal Chemistry and Drug Development has considered these concerns and recommended to incorporate the Pharmacopeia's definitions into the glossary in cases where they are clearly superior. However, in instances where the IUPAC definition was considered to be more suitable for chemists, the IUPAC definitions were retained. During the time in which this glossary was already in production, a proposed glossary was received from USP, but it was too late to make any use of it in the present version. Its recommendations will be reserved for consideration in a future update.
Considerable effort was made to make all terms in the glossary compatible with similar terms (where they exist) in the online IUPAC "Gold Book". Readers are invited to point out any errors or inconsistencies to the authors.
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GLOSSARY OF TERMS

absolute bioavailability
Fraction of the administered dose of a drug from a dosage form absorbed intact into the systemic circulation.
See also bioavailability, relative availability.
absorption (in pharmaceutics)
Process by which a drug moves from its site of administration, usually across biological membranes, to the systemic circulation or its site of action in the body.
[1]
Note:
Systemic absorption: uptake to the blood and transport via the blood of a substance to an organ or compartment in the body distant from the site of absorption.
active transport of drugs
Carriage of a solute across a biological membrane, which requires a suitable carrier and the expenditure of energy.
[2]
Additive with no intended pharmacological action, used in the formulation of dosage forms.
2.
In pharmacology, a substance added to a drug to speed or increase the action of the main component.
3.
In immunology, a substance (such as aluminum hydroxide) or an organism (such as killed mycobacterium) that increases the response to an antigen. [3] See excipient. administration (of a substance) Introduction of a substance to an organism by a defined route [3] . administration of drugs, respiratory route introduction of drugs by inhalation Delivery to the lower respiratory tract in order to obtain a local or systemic effect.
Note:
Products usually deliver the active substance in the form of aerosol droplets or solid particles (powders).
See also inhalation therapy, administration.
administration of drugs, topical route
Administration of drugs on surfaces of the body.
Note:
Topical products usually produce pharmacological effects at or near the point of application, such as the skin, eyes, nose, throat, ears, and vagina, etc., but sometimes may also have systemic effects.
See also administration.
administration of drugs, transdermal route diadermic administration percutaneous administration transcutaneous administration transdermic administration Introduction of products through unbroken skin by means of a specific drug delivery system (such as a patch containing a semi-solid formulation of the drug) for systemic and/or prolonged drug effect. See also administration.
administration of drugs, vaginal route
Introduction of products into the vagina normally for local effect.
Note:
Vaginal preparations may be liquid dispersions (solutions, foams), semi-solid (gels, creams, ointments), and solids (tablets, capsules, pessaries, tampons, sponges).
adsorption Accumulation of gases, liquids, or solutes on a solid surface, e.g., powder, polymer, glassware, syringes, etc. Process by which a compound, solid, liquid, or gas becomes loosely held by weak attraction to the surface of a solid. The attraction forces in adsorption are much weaker and less permanent than those of absorption.
Note 1:
In pharmaceutics, it mainly refers to the binding of a therapeutic agent or an impurity or a toxic material to a solid surface, or to modification of release in pharmaceutical formulations, and in analysis.
Note 2: In contrast to absorption, which is a transport phenomenon, adsorption is a surface phenomenon. In other words, it refers to accumulation of gases, liquids, or solutes on a solid surface, e.g., glassware, syringes, etc.
Note 3:
The main application of adsorption is NOT to modify release, but rather in formulation of dosage forms, purifying, charcoal adsorption (as treatment), analytics, etc. [3, 4] aerosol Mixture of small particles (solid, liquid, or a mixed variety) and a carrier gas (usually air).
Note 1:
Owing to their size, these particles (usually less than 100 µm and greater than 0.01 µm in diameter) have a comparatively small sedimentation velocity and hence exhibit some degree of stability in the earth's gravitational field.
Note 2: An aerosol may be characterized by its chemical composition, its radioactivity, the particle size distribution, the electrical charge, and the optical properties [3, 5] . 
amphipathic, amphiphilic
Molecules that contain groups with characteristically different properties, e.g., both hydrophilic and lipophilic (hydrophobic) properties.
Note:
The property of surface activity is usually due to the fact that the molecules of the substance are amphipathic or amphiphilic, meaning that each contains both a hydrophilic and a hydrophobic (lipophilic) group. [3, 6] angle of repose Characteristic angle of slope formed with the horizontal by the side of a static conical mound of powder.
inclination is sufficiently large to overcome the frictional forces, and conversely the particle will not move when the angle is below that required to overcome cohesion and adhesion.
Note 3:
The angle of repose depends on the method of measurement.
appertization
Process by which food is rendered free from pathogenic, toxigenic, and spoilage organisms.
Note 1:
A term used in the food industry.
Note 2: Appertization will not necessarily kill thermophilic spores, and thus products subjected to the process may not be sterile.
See also sterilization, disinfection.
binder Substance that acts as adhesives to bind together powders for making tablets (direct tableting) or granules (granulation) that are mainly used in tableting.
bioassay Procedure for estimating the concentration or biological activity of a substance by measuring its effect on a living system compared to a standard system [3, 12] .
Ratio of the systemic exposure from extravascular (ev) exposure to that following intravenous (iv) exposure as described by the equation:
where F is the bioavailability, A and B are areas under the (plasma) concentration-time curve following ev and iv administration, respectively, and D ev and D iv are the administered ev and iv doses.
2.
Relative amount of the administered dose of a drug that reaches systemic circulation from a certain dosage form in comparison to the amount that reaches the systemic circulation by iv administration. See also relative bioavailability. [7, 12] 
Relationship between two preparations of the same drug in the same dosage form that have a similar bioavailability.
Dosage forms containing the same drug are said to be bioequivalent if they do not differ significantly in the bioavailability (e.g., AUC, c max ., t max .) of the active constituent/ingredient, when administered in the same dose under similar experimental conditions. biological half life For a substance, the time required for the amount of a drug or a substance in a biological system to be reduced to one-half of its value by biological processes when the rate of removal is approximately exponential.
Note 1:
This is an important consideration in determining the proper amount and frequency of dose of a drug to be administered.
Note 2:
Often the rate of removal of a drug (e.g., by metabolism, excretion and/or decomposition) is not exponential.
Note 3:
Normally, the longer the biological half life, the longer is the drug present in the body. However, even a substance with an estimated short biological half life may sometimes have a significant fraction which persists in the body [3, 8] biological product Virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment, or cure of diseases or injuries in humans and/or animals.
Note:
The term "analogous product" may include essentially all biotechnology-derived products and procedures including gene therapy, transgenics, and somatic cell therapy.
biopharmaceutics Branch of pharmaceutical science that deals with the fate of drugs in the living system; particularly the release of the drug from its dosage form into a biological medium, its passage across membranes into the systemic circulation, metabolism, and elimination, and the application of this knowledge to obtain the desired therapeutic effect.
Technique that uses living organisms (or component(s) of organisms) to make or modify products, to improve plants or animals, or to develop microorganisms for specific uses. 2.
More recent usage refers to the industrial and pharmaceutical use of DNA, cell fusion, novel bioprocessing techniques, and gene therapy.
3.
The integration of life sciences with chemical, physical, and engineering sciences in order to achieve the application of organisms, cells, parts thereof, and molecular analogs for products and services [3, 6, 9] .
buccal tablet
Usually a small, flat, and soft tablet, which is designed to be placed inside the cheek to be directly absorbed through the mucosa for systemic effect.
bulk density
Characteristic of a powder rather than of individual particles given by the mass of powder occupying a known volume.
Note 1: Characteristics of importance in tablet production.
Note 2:
The bulk density is always lower than the true density of its component particles.
E. BREUER et al.
Note 3: A powder can have only one true density, but it can have many different bulk densities, depending on how tightly the particles are packed.
capsule Small edible package made usually from gelatin or other materials that can be filled with drugs (solids or liquids) to produce a unit dose, mainly for oral use. Hard capsules consist of two pieces that fit one inside the other which are produced empty and filled in a separate operation, and soft, liquid-filled capsules, which are manufactured and filled in one operation.
carrier-mediated drug transport
Transfer of a drug across a membrane by a transporter (often a protein) constituent of the cytosol membrane. Also known as active transport as opposed to passive diffusion/absorption. coacervation Separation of colloidal systems into two liquid phases. The phase more concentrated in colloid component is the coacervate, while the other phase is the equilibrium solution [6] .
coagulation Close, tight aggregation (see also flocculation) of colloid particles, emulsion droplets, suspension particles, which are difficult to redisperse. Clotting: the process of changing from a liquid to a solid, said especially of blood (i.e., blood coagulation). Transformation of a sol into a gel or semi-solid mass; e.g., the coagulation of the white of an egg by means of boiling.
Note:
When a sol is colloidally unstable (i.e., the rate of aggregation is not negligible) the formation of aggregates is called coagulation or flocculation. [6, 7] coating Technological process consisting of the application of a substance, which forms a layer (e.g, to protect the drug and/or the tablet, to mask taste, to control the rate of drug release (e.g., film coating, sugar coating).
Sugar coating is used to mask bad taste without altering release profile.
compressed tablet A solid dosage form prepared to a desired shape, usually in large-scale production, by means of high pressure in a punch and die.
Most compressed tablets consist of the active ingredient and a diluent (filler), binder, disintegrator, and lubricant.
controlled-release dosage form Medication, which due to its special technological construction provides for drug release having predefined kinetics (zero order, t 1/2 , 1 st order, etc.) at a sufficient rate to maintain the desired therapeutic level over an extended period of time.
Also used to denote sustained-release products with zero-order release kinetics. cosolvent Vehicle (often ethanol) used in combination to increase the solubility of drugs. Frequently, the solubility of a drug in a mixed solvent system is greater than can be predicted from its solubility in each solvent component separately.
cream Semi-solid emulsion for external application. Oil-in-water emulsions are most useful as water-washable bases, whereas water-in-oil emulsions are emollient and cleansing [3, 6] .
critical micelle concentration (cmc) Threshold detergent concentration at which micelle formation begins in the bulk phase. This means that all effective molecules are present as monomers at a concentration below their cmc.
Note 1:
There is a relatively narrow range of concentrations separating the limit below which virtually no micelles are detected and the limit above which virtually all additional surfactant molecules form micelles.
Note 2: Many properties of surfactant solutions, if plotted against the surfactant concentration (usually the log of concentration), appear to change at different rates above and below this range. By extrapolating the locus of such a property above and below this range until they intersect, a value may be obtained known as the critical micellization concentration (critical micelle concentration), symbol C M , abbreviation cmc (or c.m.c.) [3] .
See also inverted micelle.
critical moisture content A stage in the drying of solids, above which the drying rate (derived from the plot of the loss of moisture content against time) is linear, at which the drying rate ceases to be linear, until it reaches the equilibrium moisture content.
[10]
crossover study Type of comparative bioavailability study designed in such a way as to take into account differences in bioavailability arising from differences between patients suffering from disease, participating in the study.
Note:
The differences between the subjects may be in age, stage or severity of the disease, and prior drug treatment that some may have received. In such a crossover study, the patients are divided into two equal size groups, uniform with respect to age, body weight, sex, etc. The first group is given a specific dose of the product studied, while the second group is given a second product of proven clinical efficacy, containing the same active ingredient. After taking an appropriate number of blood samples from each individual and a washout period, the groups are reversed and the first group is given the product of proven clinical efficacy and the second is given the product being studied. This way each patient serves as his or her own control.
[11]
E. BREUER et al.
crystalline
Term that describes a solid of regular shape and the presence of three-dimensional order on the level of atomic dimensions, for a given molecule.
Note 1: Crystallinity may be detected by diffraction techniques, heat-of-fusion measurements, etc.
Note 2:
Crystalline forms are often preferred, over amorphous forms, in pharmaceutical dosage forms, due to uniformity, reproducibility, and sometimes lack of hygroscopicity. deflocculation Reversal of coagulation or flocculation, i.e., the dispersion of aggregates to form a stable colloidal suspension or emulsion. See also flocculation. [3, 5] delayed-release dosage form Pharmaceutical preparation that releases the drug(s) at a time other than promptly after administration.
Note:
Typically, this is related to enteric coated tablets.
deliquescence Process that occurs when the vapor pressure of the saturated aqueous solution of a substance is less than the vapor pressure of water in the ambient air.
When water vapor is collected by the pure solid compound, a mixture of the solid and liquid or an aqueous solution of the compound forms until the substance is dissolved and is in equilibrium with its environment; at this time the vapor pressure of water over the aqueous solution will equal the partial pressure of water in the atmosphere in contact with it. A crystalline salt aerosol particle will deliquesce in the atmosphere when the relative humidity surpasses a characteristic value, the so-called deliquescence point [3] .
deliquescent
Substance that absorbs sufficient moisture from the atmosphere to dissolve itself.
depot
Deposit of a drug in a body created by injection or by a similar mode of introduction to form a source of slow release.
detergency Property, which serves as basis for the process whereby surfactants are used for the removal of foreign matter from surfaces (including dirt from clothes or body surfaces). See also detergents, solubilizing, surface-active agent, surfactant.
detergent Surfactant (or a mixture containing one or more surfactants) having cleaning properties in dilute solutions (soaps are surfactants and detergents) [3] .
diffusion barrier
Obstacle such as coating or embedding, which acts as a factor controlling the rate of drug release.
Note:
Body fluids or membranes can also act as barriers.
disperse system Dosage form in which the active ingredient is insoluble in the carrier; includes aerosols (solids or liquids in gas), suspensions (solids in liquids), emulsions (liquids in liquids), and foams (gas in liquid), or ointments/creams (solid in solid or in semi-solid, or liquid in solid).
These systems are thermodynamically unstable and need to be stabilized by suspensifying or emulsifying agents. 
They can be designed for administration by all possible administration routes to achieve the desired therapeutic response.
dosage regimen Dose and dosing interval of a drug. drug Biologically active substance, which when biodistributed in the body is expected to modify one or more of its functions.
Note 1:
Frequently used synonyms from formulated drugs (see dosage forms) are: medicine, medication, remedy.
Note 2:
The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances [3, 12] .
drug delivery system
Sophisticated dosage form, which, by its construction, is able to modify/control the availability of the drug substance to the body by temporal or spatial considerations. 
drug-eluting stent
Refers to a stent with an active drug that is intended to produce a therapeutic effect (e.g., reduction of restenosis) [13] .
dusting powder
Usually intended for external use.
Note 1: Usually contains ingredients used for therapeutic, prophylactic, or lubricant purposes.
Note 2:
Normally dispensed in containers with perforated lids.
Note 3:
The powder must flow well so that it can be dusted over the required area.
Note 4:
Examples are antibacterial and antifungal products.
effervescent tablet
Solid preparation that on contact with water breaks apart by the effect of gas (usually CO 2 ) evolution, resulting commonly from the reaction of hydrogen carbonate with citric or tartaric acid, in order to facilitate dissolution or dispersion of the active ingredient before ingestion.
efflorescence Opposite of deliquescence; the drying of a salt solution when the vapor pressure of water in the saturated solution of a substance is greater than the partial pressure of water in the ambient air. Also refers to the loss of water of crystallization from a solid salt such as Na 2 CO 3 ؒ10H 2 O [3] .
efflorescent
Substance that loses water to form a lower hydrate or becomes anhydrous spontaneously.
elixir Sweet (often colored) dilute alcohol-based, "hydroalcoholic", liquid used in the compounding of drugs to be taken by mouth in order to improve palatability.
Note:
Elixirs are among the most common types of medicinal preparations taken orally in liquid form.
elutriation
The process of separating the lighter particles of a powder from the heavier ones by means of an upward-directed stream of fluid (gas or liquid). [3, 7] embedding Technological process, which consists of mixing or inclusion of the therapeutic substance with an excipient or their mixtures, typically as a matrix dosage form, in order to change the rate of release.
emulsion Fluid colloidal dispersion system in which liquid droplets and/or liquid crystals are dispersed in a liquid.
Note 1:
The droplets often exceed the usual limits for colloids in size.
Note 2: An emulsion is denoted by the symbol o/w if the continuous phase is an aqueous solution and by w/o if the continuous phase is an organic liquid (an "oil").
Note 3:
More complicated double emulsions such as o/w/o (i.e., oil droplets contained within aqueous droplets dispersed in a continuous oil phase) are also possible [3] .
encapsulation Process of enclosing a drug in a (micro or nano) particle (capsule, liposome, polymer).
enemas Solutions (aqueous or oily), emulsions, or suspensions for rectal administration of medicaments for cleansing, diagnostic, or therapeutic purposes.
enteric coating
Used on tablets, granules, pellets, and capsules to make them resistant to gastric fluids but designed to disintegrate, disrupt, or dissolve when the preparation enters the duodenum.
Note:
Enteric coating is used for one of the following reasons: • To protect the drug from degradation by the acid in the stomach (e.g., erythromycin).
• To protect the stomach from the irritant effect of the drug (e.g., aspirin 
gastric emptying rate
Pace at which a drug along with the stomach content leaves and enters the duodenum.
Note 1: Often, gastric emptying rate is also expressed as gastric emptying time.
Note 2: Gastric emptying rate (or time) is expressed typically in units of time or t 1/2 . It is also expressed as the amount of a given substance emptied per the total mass in the stomach, at a given time; or as the amount emptied, at a given time, of a given substance.
Note 3:
Since most drugs are optimally absorbed from the small intestine, the onset of drug action depends on the gastric emptying rate. Thus, the rate of gastric emptying determines the timing but not the extent of oral drug absorption.
Note 4:
The gastric emptying rate depends on several factors, e.g., stomach calorie content, pH, hunger, anxiety, the nature of the drugs and body posture. High-calorie foods (e.g., fats) usually retard gastric emptying and delay drug absorption.
[15]
gel Colloidal system with a finite, usually rather small yield stress. Non-fluid colloidal network or polymer network that is expanded throughout its whole volume by a fluid. [5, 6] gene therapy Use of products containing genetic material (e.g., pDNA, antisense DNA, siRNA) to treat a disease or condition, or to modify or manipulate the expression of genetic material or to alter the biological properties of living cells.
generic(s)
Drug(s) or formulation(s) of drug(s) or dosage forms, which no longer have patent protection.
Note 1:
Generic or nonproprietary drugs that may enter the market after the expiry of the basic patent covering the original drugs.
Note 2:
Nonproprietary drugs are required to meet the same bioequivalency test as the original brand name drugs.
Note 3: Generic products may themselves bear brand names.
gradual release
See sustained release.
granules Powder particles, which have been aggregated to form larger irregular particles, usually of 0.5-2 mm diameter.
Note 1: Granules are also used as intermediates in tableting. These are typically of smaller sizes.
Note 2:
May also be used rarely as independent dosage form for oral administrations.
See also tablet.
granulation Process in which powder particles are made to aggregate to larger particles called granules.
Note 1:
In the majority of cases, granulation is required in the production of tablets or capsules, when granules are made as an intermediate product.
Note 2:
Granulation is preceded by mixing the necessary powdered ingredients to assure their uniform distribution in the granules.
E. BREUER et al.
Note 3: Granulation may be carried out by two methods: wet granulations which utilize nontoxic volatile liquids, like water or low alcohols; or dry methods in which high pressure is applied.
See also binders, granules.
half life, t 1/2 half time Time required for the concentration of a reactant in a given reaction to reach a value that is the arithmetic mean of its initial and final (equilibrium) values. For a reactant that is entirely consumed, it is the time taken for the reactant concentration to fall to one-half of its initial value.
Note:
The half life of a reaction has meaning only in special cases: 1.
For a first-order reaction, the half life of the reactant may be called the half life of the reaction.
2.
For a reaction involving more than one reactant, with the concentrations of the reactants in their stoichiometric ratios, the half life of each reactant is the same, and may be called the half life of the reaction. If the concentrations of reactants are not in their stoichiometric ratios, there are different half lives for different reactants, and one cannot speak of the half life of the reaction.
See also biological half life. [3, 12] hydrate Crystalline form of a compound in which water molecules are part of the crystal structure.
hydrophilicity
Tendency of a molecule to be solvated by water. [3, 17] hydrophobicity Property of being water-repellent; tending not to absorb water.
Note:
Hydrophobic interaction could result from hydrophobicity; the thermodynamic tendency of molecules or groups to escape from an aqueous environment resulting in the association of nonpolar groups. [3, 17] hygroscopicity Tendency of a substance to absorb water from the atmosphere.
A substance that absorbs moisture from the atmosphere is called hygroscopic.
immediate-release tablet
Dosage form that releases the drug immediately. See also fast-dissolving tablet, in contrast to sustained-release tablet.
implantation Insertion or grafting of a biological, living, inert, or radioactive material into the body.
implants
Small sterile usually polymeric matrices, pellets, or particles for insertion or implanting into the body by surgical means or by injection to help achieve sustained release.
inactivation factor (IF)
Number that expresses the reduction in the numbers of a microorganism, brought about by a sterilization process.
Note:
The IF value is specific for a microorganism and a sterilization process.
inhalation therapy
Administration of drugs directly to the respiratory tract, mostly by aerosols.
minimum effective plasma concentration
Concentration of a drug that must be achieved in the plasma before any desired therapeutic or pharmacological effect can be obtained.
minimum inhibitory concentration (MIC)
Lowest concentration of an antibacterial drug necessary to inhibit the growth of a microorganism.
minimum therapeutic plasma concentration
See minimum effective plasma concentration.
modified release
Release of a drug from a dosage form that it is not immediate (e.g., sustained release, retarded release, delayed-action preparations, controlled release, extended release, etc.).
moistening agents
Usually water or low-molecular-weight alcohols or compounds, used in topical applications and in wet granulation, for the production of tablets.
multicompartment formulation
Dosage form (capsule, tablet) comprising several elements (e.g., microspheres or coated pellets) differing in the rate of drug release.
multilayer tablet
Consists of several different layers that are compressed on top of each other, to form a single tablet composed of two or more layers.
